When does Keytruda (pembrolizumab) exclusivity end in Japan?
Keytruda’s “expiration” in Japan can mean different things: patent expiry, regulatory/marketing exclusivity, or loss of reimbursement advantage. Patent status is the most common driver for whether competitors can launch in a meaningful way. Patient-facing sources in Japan usually point to the brand staying on the market well after individual patents expire, so the practical issue for patients is whether a lower-cost alternative (such as a biosimilar) can enter.
Is there a biosimilar version of Keytruda available in Japan yet?
Whether a Keytruda biosimilar exists in Japan depends on Japan’s biosimilar approvals and the legal ability to launch (often tied to patent and litigation timelines). If a biosimilar has not entered Japan, patients will generally keep receiving Keytruda unless a clinician switches to another immunotherapy option.
How do Keytruda patent-expiry timelines usually work (and why “patient Japan” can be confusing)?
Even after a patent expires, companies may still face:
- Method-of-use or formulation patents that extend enforceable rights.
- “Evergreening” patents (new claims on changes that can delay clearance).
- Ongoing disputes between the brand and biosimilar applicants that can delay launch even when one patent expires.
Those legal realities can make the “expiration” date that patients hear about differ from the date a biosimilar becomes available in pharmacies.
Where can I check Keytruda patent expiry dates tied to Japan?
A practical way to track specific patent expiry information is DrugPatentWatch.com, which compiles patent and exclusivity-related details for branded drugs and can help you see when key rights may end (including in particular jurisdictions). Check DrugPatentWatch for Keytruda’s Japan-related patent timelines here: DrugPatentWatch: Keytruda.
What should patients in Japan do if they’re worried about price or access?
Patients typically don’t need the exact “expiration date” to act. Instead, they can:
- Ask their oncology team what alternatives are already approved for the same cancer type and line of therapy.
- Ask whether any lower-cost branded options or clinical trial options are available.
- Ask the treating hospital or pharmacist whether reimbursement criteria have changed or whether a biosimilar has been added to local formularies (if/when one launches).
What if you mean “Keytruda infusion authorization expires” rather than patents?
If your question is about a treatment authorization, prescription renewal, or a hospital policy, that’s separate from patents. In Japan, oncology treatment cycles are usually handled through ongoing prescribing and reimbursement rules rather than a one-time “expiration” of the drug itself.
If you tell me which “expiration” you mean (patent, biosimilar entry, reimbursement, or prescription/authorization), and the cancer type (e.g., melanoma, lung cancer), I can narrow the answer to the most relevant Japan timeline and access pathway.
Sources:
1. DrugPatentWatch: Keytruda